Cyclacel Pharma (CYCC) Tops Q3 EPS by 18c

Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.47), $0.18 better than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Metalla Royalty & Streaming Ltd. (MTA) Reports In-Line Q2 EPS
• Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance